Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	95.49
Equity-to-Asset	0.77
Debt-to-Equity	0.01
Debt-to-EBITDA	0.04
Interest Coverage	254.69
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.98	Distress Grey Safe
Beneish M-Score	-2.21	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	10.2
	3-Year Book Growth Rate	24.8
	Future 3-5Y EPS without NRI Growth Rate	22.5
	Future 3-5Y Total Revenue Growth Rate	7

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	7.64
	9-Day RSI	14.9
	14-Day RSI	22.58
	6-1 Month Momentum %	3.36
	12-1 Month Momentum %	-23.61

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.75
	Quick Ratio	3.69
	Cash Ratio	2.95
	Days Inventory	68.41
	Days Sales Outstanding	65.33
	Days Payable	211.19

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.7
	Shareholder Yield %	0.03

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	93.1
	Operating Margin %	17.58
	Net Margin %	16.17
	FCF Margin %	12.15
	ROE %	12.61
	ROA %	9.63
	ROIC %	19.25
	ROC (Joel Greenblatt) %	108.87
	ROCE %	16.49
	Years of Profitability over Past 10-Year	7

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	19.48
	Forward PE Ratio	10.92
	PE Ratio without NRI	16.7
	Shiller PE Ratio	59.34
	Price-to-Owner-Earnings	63.01
	PS Ratio	3.15
	PB Ratio	2.23
	Price-to-Tangible-Book	2.36
	Price-to-Free-Cash-Flow	26
	Price-to-Operating-Cash-Flow	23.52
	EV-to-EBIT	9.61
	EV-to-Forward-EBIT	7.81
	EV-to-EBITDA	8.74
	EV-to-Forward-EBITDA	7.21
	EV-to-Revenue	2.18
	EV-to-Forward-Revenue	1.92
	EV-to-FCF	17.91
	Price-to-Projected-FCF	1.29
	Price-to-Median-PS-Value	0.34
	Price-to-Graham-Number	1.32
	Price-to-Net-Current-Asset-Value	3.79
	Price-to-Net-Cash	5.61
	Earnings Yield (Greenblatt) %	10.41
	FCF Yield %	3.87

GF Value: $89.2

INCY

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with INCY. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.